KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Cash: 2016-2024

Historic Change in Cash for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $19.3 million.

  • Amneal Pharmaceuticals' Change in Cash rose 438.71% to $154.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.1 million, marking a year-over-year increase of 1027.25%. This contributed to the annual value of $19.3 million for FY2024, which is 69.77% down from last year.
  • Amneal Pharmaceuticals' Change in Cash amounted to $19.3 million in FY2024, which was down 69.77% from $63.9 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Change in Cash registered a high of $194.3 million during FY2020, and its lowest value of -$221.5 million during FY2022.
  • Its 3-year average for Change in Cash is -$46.1 million, with a median of $19.3 million in 2024.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Change in Cash spiked by 394.58% in 2020 and then plummeted by 146.52% in 2021.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Change in Cash stood at $194.3 million in 2020, then plummeted by 146.52% to -$90.4 million in 2021, then slumped by 145.08% to -$221.5 million in 2022, then soared by 128.84% to $63.9 million in 2023, then tumbled by 69.77% to $19.3 million in 2024.